Y Intercept Hong Kong Ltd Acquires New Stake in Intuitive Surgical, Inc. $ISRG

Y Intercept Hong Kong Ltd bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,487 shares of the medical equipment provider’s stock, valued at approximately $10,057,000.

Several other institutional investors and hedge funds have also bought and sold shares of ISRG. Tobam boosted its holdings in shares of Intuitive Surgical by 666.7% in the second quarter. Tobam now owns 46 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 40 shares during the last quarter. Kilter Group LLC bought a new position in Intuitive Surgical in the second quarter worth approximately $27,000. Princeton Global Asset Management LLC purchased a new position in shares of Intuitive Surgical during the 2nd quarter worth $30,000. Riggs Asset Managment Co. Inc. boosted its stake in shares of Intuitive Surgical by 84.2% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 32 shares during the last quarter. Finally, First Command Advisory Services Inc. grew its position in shares of Intuitive Surgical by 3,750.0% during the 2nd quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 75 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Craig H. Barratt sold 750 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total transaction of $435,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Henry L. Charlton sold 13,731 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total transaction of $7,963,980.00. Following the completion of the sale, the executive vice president owned 3,056 shares in the company, valued at $1,772,480. This represents a 81.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 55,714 shares of company stock worth $31,617,799. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $523.99 on Friday. The firm has a market cap of $187.84 billion, a price-to-earnings ratio of 66.41, a P/E/G ratio of 4.28 and a beta of 1.67. The firm has a fifty day moving average price of $562.32 and a 200 day moving average price of $511.79. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.18%. The business had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the prior year, the firm earned $2.21 EPS. The business’s revenue was up 18.8% on a year-over-year basis. As a group, research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q4 results beat Wall Street: Revenue and adjusted EPS topped estimates, backed by higher procedure volumes and system demand — a primary near?term driver of recurring instrument sales. Reuters: Intuitive Surgical beats quarterly estimates on demand for surgical robots
• Positive Sentiment: Analysts boost some targets and reaffirm conviction: Bernstein raised its target sharply (big upside), Raymond James and BTIG reaffirmed/outperform with higher targets — supporting upside potential from elongation of the company’s growth runway. Benzinga: Analysts revise forecasts after Q4
• Neutral Sentiment: Guidance is measured: Management expects mid?teens da Vinci procedure growth (midpoint ~14%) and 2026 gross margin around 67–68%, while flagging higher operating expenses for R&D — signaling steady growth but potential margin/operating?leverage moderation. MarketBeat: Intuitive Surgical Just Proved the Growth Engine Still Runs
• Neutral Sentiment: JURA clinical update and milestone PRs add long?term optionality: Early imaging data from the JURA feasibility study and a new 20 million?patient da Vinci milestone reinforce long?term growth narratives beyond core platforms. TipRanks: JURA feasibility study update GlobeNewswire: 20 Million Patients Benefit from da Vinci Surgery
• Negative Sentiment: Tariffs and gross?margin pressure noted: Management expects tariffs to cut gross margins (about a 1.2% headwind in 2026) and flagged some gross?margin decline vs. recent quarters — a medium?term profitability risk. Zacks: Q4 beat but gross margin declines
• Negative Sentiment: Mixed analyst moves and a few downgrades: Some firms trimmed targets or moved to in?line/hold (Evercore, Zacks), creating near?term debate over valuation vs. growth and muting upside for traders focused on short?term catalysts. The Fly: Evercore lowers price target

Analyst Ratings Changes

ISRG has been the subject of a number of analyst reports. Mizuho set a $575.00 price target on Intuitive Surgical in a research report on Wednesday, October 22nd. Daiwa Capital Markets increased their target price on shares of Intuitive Surgical from $510.00 to $550.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $714.00 price target on shares of Intuitive Surgical in a report on Friday, January 9th. Argus upped their price target on shares of Intuitive Surgical from $600.00 to $630.00 in a research report on Monday, October 27th. Finally, BTIG Research restated a “buy” rating and set a $616.00 price objective on shares of Intuitive Surgical in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $617.57.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.